Outcomes according to MN1 expression status in all CN-AML patients 60 years of age or older and, separately, in those 60-69 years of age and 70 years of age or older
| Outcome . | Low MN1 . | High MN1 . | P* . | OR/HR (95% CI) . |
|---|---|---|---|---|
| All patients | n = 70 | n = 70 | ||
| CR rate, no. (%) | 56 (80) | 37 (53) | .001 | 3.57 (1.68, 7.56) |
| DFS | .29 | 0.79 (0.51, 1.23) | ||
| Median, y | 0.9 | 0.6 | ||
| Disease-free at 3 y, % (95% CI) | 18 (9-29) | 11 (3-23) | ||
| OS | .03 | 0.68 (0.48, 0.96) | ||
| Median, y | 1.2 | 0.8 | ||
| Alive at 3 y, % (95% CI) | 23 (14-33) | 10 (4-18) | ||
| EFS | .004 | 0.50† (0.33, 0.76) | ||
| Median, y | 0.7 | 0.2 | ||
| Event-free at 3 y, % (95% CI) | 14 (7-23) | 6 (2-13) | ||
| Patients 60-69 y | n = 44 | n = 35 | ||
| CR rate, no. (%) | 35 (80) | 19 (54) | .03 | 3.28 (1.22, 8.81) |
| DFS | .82 | 0.94 (0.52, 1.69) | ||
| Median, y | 0.7 | 0.5 | ||
| Disease-free at 3 y, % (95% CI) | 9 (2-21) | 11 (2-28) | ||
| OS | .44 | 0.83 (0.52, 1.33) | ||
| Median, y | 1.1 | 0.8 | ||
| Alive at 3 y, % (95% CI) | 18 (9-31) | 11 (4-24) | ||
| EFS | .11 | 0.69 (0.44, 1.10) | ||
| Median, y | 0.6 | 0.2 | ||
| Event-free at 3 y, % (95% CI) | 7 (2-17) | 6 (1-17) | ||
| Patients 70 y or older | n = 26 | n = 35 | ||
| CR rate, no. (%) | 21 (81) | 18 (51) | .03 | 3.97 (1.22, 12.90) |
| DFS | .09 | 0.54 (0.27, 1.10) | ||
| Median, y | 1.3 | 0.7 | ||
| Disease-free at 3 y, % (95% CI) | 33 (15-53) | 11 (2-30) | ||
| OS | .006 | 0.46 (0.26, 0.81) | ||
| Median, y | 2.0 | 0.9 | ||
| Alive at 3 y, % (95% CI) | 31 (15-49) | 9 (2-21) | ||
| EFS | .007 | 0.48 (0.27, 0.84) | ||
| Median, y | 1.0 | 0.3 | ||
| Event-free at 3 y, % (95% CI) | 27 (12-44) | 6 (1-17) |
| Outcome . | Low MN1 . | High MN1 . | P* . | OR/HR (95% CI) . |
|---|---|---|---|---|
| All patients | n = 70 | n = 70 | ||
| CR rate, no. (%) | 56 (80) | 37 (53) | .001 | 3.57 (1.68, 7.56) |
| DFS | .29 | 0.79 (0.51, 1.23) | ||
| Median, y | 0.9 | 0.6 | ||
| Disease-free at 3 y, % (95% CI) | 18 (9-29) | 11 (3-23) | ||
| OS | .03 | 0.68 (0.48, 0.96) | ||
| Median, y | 1.2 | 0.8 | ||
| Alive at 3 y, % (95% CI) | 23 (14-33) | 10 (4-18) | ||
| EFS | .004 | 0.50† (0.33, 0.76) | ||
| Median, y | 0.7 | 0.2 | ||
| Event-free at 3 y, % (95% CI) | 14 (7-23) | 6 (2-13) | ||
| Patients 60-69 y | n = 44 | n = 35 | ||
| CR rate, no. (%) | 35 (80) | 19 (54) | .03 | 3.28 (1.22, 8.81) |
| DFS | .82 | 0.94 (0.52, 1.69) | ||
| Median, y | 0.7 | 0.5 | ||
| Disease-free at 3 y, % (95% CI) | 9 (2-21) | 11 (2-28) | ||
| OS | .44 | 0.83 (0.52, 1.33) | ||
| Median, y | 1.1 | 0.8 | ||
| Alive at 3 y, % (95% CI) | 18 (9-31) | 11 (4-24) | ||
| EFS | .11 | 0.69 (0.44, 1.10) | ||
| Median, y | 0.6 | 0.2 | ||
| Event-free at 3 y, % (95% CI) | 7 (2-17) | 6 (1-17) | ||
| Patients 70 y or older | n = 26 | n = 35 | ||
| CR rate, no. (%) | 21 (81) | 18 (51) | .03 | 3.97 (1.22, 12.90) |
| DFS | .09 | 0.54 (0.27, 1.10) | ||
| Median, y | 1.3 | 0.7 | ||
| Disease-free at 3 y, % (95% CI) | 33 (15-53) | 11 (2-30) | ||
| OS | .006 | 0.46 (0.26, 0.81) | ||
| Median, y | 2.0 | 0.9 | ||
| Alive at 3 y, % (95% CI) | 31 (15-49) | 9 (2-21) | ||
| EFS | .007 | 0.48 (0.27, 0.84) | ||
| Median, y | 1.0 | 0.3 | ||
| Event-free at 3 y, % (95% CI) | 27 (12-44) | 6 (1-17) |
OR indicates the odds of achieving a CR for low MN1 vs high MN1 expressers; HR, the hazard of having an event for low MN1 vs high MN1 expressers; and CI, confidence interval.
P values for categorical variables are from Fisher exact test. P values for time-to-event variables are from the log-rank test (OS, DFS, and EFS).
Does not meet the proportional hazards assumption, HR reported at 3 months.